{"id":"W3214653934","doi":"10.1158/2159-8290.cd-21-1141","title":"Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Takeda Oncology; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Natera; Chugai Pharmaceutical; Seagen; Array BioPharma; OncoSec Medical; Pfizer; Incyte; AstraZeneca; Amarin Corporation; Castle Biosciences; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Sanofi; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Ipilimumab; Pembrolizumab; Adjuvant; Melanoma; Blockade; Immunotherapy; Adjuvant therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001317369,0.0002471228,0.0004964283,0.0001345911,0.00007886041,0.00006504438,0.0001332356,0.000150532,0.001503062],"category_scores_gemma":[0.0001316453,0.0001943137,0.0001774041,0.0007406392,0.0001159218,0.0002737744,0.00007255167,0.0003462411,0.00002367117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007975558,"about_ca_system_score_gemma":0.001586142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003577292,"about_ca_topic_score_gemma":0.01125585,"domain_scores_codex":[0.9981639,0.0001061929,0.000397818,0.0005300103,0.0003494313,0.0004526183],"domain_scores_gemma":[0.9989394,0.0001537361,0.0001213921,0.0005765372,0.00009888578,0.0001100791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4502743,0.001575036,0.1470165,0.0009241356,0.002976313,0.005592603,0.002340528,0.0001947821,0.1137772,0.0004177005,0.04163101,0.2332799],"study_design_scores_gemma":[0.113567,0.002807999,0.7039916,0.001759077,0.0006947867,0.0002021178,0.002152616,0.0002228807,0.1213448,0.0001880027,0.05191251,0.001156598],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824929,0.01199035,0.00002447879,0.001061824,0.001895043,0.0003054511,0.0001996074,0.00006039064,0.001969912],"genre_scores_gemma":[0.982501,0.009326064,0.0000694619,0.0005296164,0.000451752,0.0001152294,0.0001175778,0.00004828633,0.006840956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5569751,"threshold_uncertainty_score":0.9994097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02601356629115556,"score_gpt":0.3044026289868365,"score_spread":0.2783890626956809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}